⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Home/Drugs/Retatrutide

Retatrutide

Retatrutide

Phase 3

Sponsor: Eli Lilly

Indication: MASH / Obesity

Mechanism of Action

Triple Agonist (GLP-1/GIP/Glucagon)

Target: GLP-1Target: GIPTarget: Glucagon

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

RECRUITINGNCT07467447

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

Phase:PHASE2Org:Hudson Biotech

ACTIVE_NOT_RECRUITING

Relevant Publications (PubMed)

Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions.

Lian J, Lareu RR, Patil M et al.

Liver Int2026 Apr

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.

Abulehia A, Ayesh H, Ayesh O et al.

Endocrinol Diabetes Metab2026 Mar

Retatrutide in type 2 diabetes mellitus and obesity: an overview.

Panou T, Gouveri E, Popovic DS et al.

Expert Rev Clin Pharmacol2026 Mar 10

Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.

Validated Models

This drug has been validated in the following preclinical models:

NCT06662383

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Phase:PHASE3Org:Eli Lilly and Company

RECRUITINGNCT07035093

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Phase:PHASE3Org:Eli Lilly and Company

COMPLETEDNCT05611957

A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function

Phase:PHASE1Org:Eli Lilly and Company

COMPLETEDNCT05931367

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Phase:PHASE3Org:Eli Lilly and Company

View all trials on ClinicalTrials.gov

Briand F, Le Cudennec C, Grasset E et al.

Obesity (Silver Spring)2026 Feb 25

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.

Hitaka K, Sugawara T, Matsumoto M et al.

Int J Obes (Lond)2026 Feb 21

View more on PubMed